Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Melanoma 3HIV Infections 2Carcinoma, Hepatocellular 2Acquired Immunodeficiency Syndrome 2Stomach Ulcer 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sarcoma, Kaposi 1Sarcoma 1Neoplasms 1Muscle Neoplasms 1Hepatitis B 1Duodenal Ulcer 1Adenoviridae Infections 1AIDS-Related Complex 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 93Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 51Doxorubicin 50atezolizumab 48trametinib 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms × Tumor Necrosis Factor-alpha × Clear all
NCT00019968 2023-10-31

Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tissue Sarcoma of the Arm or Leg

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
Sarcoma

Neoplasms, Sarcoma, Muscle Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡